Literature DB >> 29701613

Hydrazone linked doxorubicin-PLA prodrug nanoparticles with high drug loading.

Simone Gatti1, Azzurra Agostini, Umberto Capasso Palmiero, Claudio Colombo, Marco Peviani, Alessandra Biffi, Davide Moscatelli.   

Abstract

An optimal drug delivery system should be characterized by biocompatibility, biodegradability, high drug loading and favorable drug release profile. To achieve this goal a hydrazone linked doxorubicin-poly(lactic acid) prodrug (PLA-DOX) was synthesized by the functionalization of a short polymer chain produced by ring opening polymerization. The hydrophobic prodrug generated in this way was nanoprecipitated using a block copolymer to form polymeric nanoparticles (NPs) with a quantitative loading efficiency and a high and tunable drug loading. The effects of the concentration of the PLA-DOX prodrug and surfactant were studied by dynamic light scattering showing a range of NP size between 50 and 90 nm and monodispersed size distributions with polydispersity indexes lower then 0.27 up to a maximum DOX concentration of 27% w/w. The release profile of DOX from these NPs, tested at different pH conditions, showed a higher release rate in acidic conditions, consistent with the nature of the hydrazone bond which was used to conjugate the drug to the polymer. In vitro cytotoxicity studies performed on BV2 microglia-like cell line highlighted a specific cytotoxic effect of these NPs suggesting the maintenance of the drug efficacy and a modified release profile upon encapsulation of DOX in the NPs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29701613     DOI: 10.1088/1361-6528/aac0d3

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  1 in total

1.  Synergistic inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein/DOX nanodispersions.

Authors:  Ruoning Wang; Yujie Yang; Mengmeng Yang; Dandan Yuan; Jinyu Huang; Rui Chen; Honglan Wang; Lihong Hu; Liuqing Di; Junsong Li
Journal:  J Nanobiotechnology       Date:  2020-08-26       Impact factor: 10.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.